
April 14 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:
IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDE
IRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVES
IRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVAL
IRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGN